| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
| Ausblick | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Hoffmann Family | 64.97 |
| Freefloat | 27.20 |
| Maja Oeri | 7.58 |
| Stichting Pensioenfonds ABP (Global Equity Portfolio) | 1.39 |
| RBC Global Equity Focus Fund | 0.92 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 94'442 | 97'735 | 101'465 | 100'920 | 103'613 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.60 | 0.63 | 0.57 | 0.62 | 0.61 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 32'244 | 31'254 | 32'942 | 35'627 | 33'816 |
| Summe Anlagevermögen | 46'392 | 48'329 | 51'752 | 57'041 | 54'536 |
| Summe Aktiva | 78'517 | 83'091 | 86'138 | 92'317 | 88'151 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 18'770 | 15'582 | 15'411 | 32'552 | 26'544 |
| Summe Fremdkapital | 48'151 | 47'224 | 46'365 | 63'972 | 56'136 |
| Summe Eigenkapital | 30'366 | 35'867 | 39'773 | 28'345 | 32'015 |
| Summe Passiva | 78'517 | 83'091 | 86'138 | 92'317 | 88'151 |
Adresse
| Grenzacherstrasse 124, 4058 Basel | |
| Telefon | +41 (61) 688-11-11 |
| Fax | +41 (61) 691-93-91 |
| URL | http://www.roche.com |
Management
|
Akiko Iwasaki
Director |
|
Alan Hippe
Chief Financial & Information Officer |
|
André S. Hoffmann
Vice Chairman |
|
Anita Hauser
Independent Non-Executive Director |
|
Annette Luther
Secretary |
|
Bernard J. Poussot
Independent Non-Executive Director |
|
Bruno Eschli
Head-Investor Relations |
|
Claudia Boeckstiegel
General Counsel |
|
Claudia Süssmuth Dyckerhoff
Independent Non-Executive Director |
|
Cristina A. Wilbur
Chief People Officer |
|
Hans Clevers
Head-Pharma Research & Early Development |
|
Jemilah Mahmood
Director |
|
Joerg Duschmale
Independent Non-Executive Director |
|
Levi A. Garraway
Chief Medical Officer & Head-Product Development |
|
Pascale Schmidt
Chief Compliance Officer |
|
Patrick Frost
Independent Non-Executive Director |
|
Richard P. Lifton
Independent Non-Executive Director |
|
Severin Schwan
Chairman |
|
Silke Hörnstein
Head-Corporate Strategy & Sustainability |
|
Thomas Schinecker
Chief Executive Officer |
|
Ulf Mark Schneider
Director |